Visceral leishmaniasis during childhood in southern Greece

被引:49
作者
Maltezou, HC
Siafas, C
Mavrikou, M
Spyridis, P
Stavrinadis, C
Karpathios, T
Kafetzis, DA [1 ]
机构
[1] Univ Athens, P&A Kyriakou Childrens Hosp, Dept Pediat 2, GR-11527 Athens, Greece
[2] Univ Athens, P&A Kyriakou Childrens Hosp, Dept Pediat 1, GR-11527 Athens, Greece
关键词
D O I
10.1086/317455
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Records were reviewed of 82 immunocompetent children (median age, 2.5 years) from southern Greece who were diagnosed with visceral leishmaniasis from 1986 through 1998. Forty-nine (58%) patients originated from the city of Athens; of them, 46 (94%) lived by hills bordering the city. The median interval from the onset of symptoms to admission was 10 days. Fever and splenomegaly were observed in >95% of the patients. Thrombocytopenia was the most frequent hematological finding (80%), All patients were treated with meglumine antimonate; 20 (24%) of them were partially treated on an outpatient basis. Rapid clinical response was noted in all patients but one. Five patients relapsed; 3 responded to reintroduction of meglumine antimonate, 1 responded to liposomal amphotericin B, and 1 underwent splenic artery ligation. We conclude that pentavalent antimonials remain the first choice of treatment for visceral leishmaniasis in immunocompetent children in areas where resistance has not become a problem, It is possible to treat affected patients with outpatient administration of these agents, making them feasible options for therapy.
引用
收藏
页码:1139 / 1143
页数:5
相关论文
共 15 条
[1]   TREATMENT OF VISCERAL LEISHMANIASIS WITH PENTAVALENT ANTIMONY AND INTERFERON-GAMMA [J].
BADARO, R ;
FALCOFF, E ;
BADARO, FS ;
CARVALHO, EM ;
PEDRALSAMPAIO, D ;
BARRAL, A ;
CARVALHO, JS ;
BARRALNETTO, M ;
BRANDELY, M ;
SILVA, L ;
BINA, JC ;
TEIXEIRA, R ;
FALCOFF, R ;
ROCHA, H ;
HO, JL ;
JOHNSON, WD .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) :16-21
[2]  
BERMAN JD, 1988, REV INFECT DIS, V10, P560
[3]   Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[4]   US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis - Editorial response [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :49-51
[5]   Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome) [J].
Davidson, RN ;
diMartino, L ;
Gradoni, L ;
Giacchino, R ;
Gaeta, GB ;
Pempinello, R ;
Scotti, S ;
Cascio, A ;
Castagnola, E ;
Maisto, A ;
Gramiccia, M ;
diCaprio, D ;
Wilkinson, RJ ;
Bryceson, ADM .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) :938-943
[6]   Treatment of visceral leishmaniasis in children with liposomal amphotericin B [J].
diMartino, L ;
Davidson, RN ;
Giacchino, R ;
Scotti, S ;
Raimondi, F ;
Castagnola, E ;
Tasso, L ;
Cascio, A ;
Gradoni, L ;
Gramiccia, M ;
PettoelloMantovani, M ;
Bryceson, ADM .
JOURNAL OF PEDIATRICS, 1997, 131 (02) :271-277
[7]   EPIDEMIOLOGY OF VISCERAL LEISHMANIASIS IN NORTHEAST BRAZIL [J].
EVANS, TG ;
TEIXEIRA, MJ ;
MCAULIFFE, IT ;
VASCONCELOS, IDB ;
VASCONCELOS, AW ;
SOUSA, AD ;
LIMA, JWD ;
PEARSON, RD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) :1124-1132
[8]  
HARRISON LH, 1986, REV INFECT DIS, V8, P447
[9]   Leishmaniasis [J].
Herwaldt, BL .
LANCET, 1999, 354 (9185) :1191-1199
[10]   The contrasting roles of CD4(+) T cells in intracellular infections in humans: Leishmaniasis as an example [J].
Kemp, M ;
Theander, TG ;
Kharazmi, A .
IMMUNOLOGY TODAY, 1996, 17 (01) :13-16